Peré Domingo

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 372 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Cristina Tural, Christopher Holtzer, Jonathan Schapiro et al. · AIDS · 2002 · 312 citations

Pharmacy, Pharmacotherapy, Clinical Pharmacology +16

Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection

Estebán Martínez, Juan A. Arnaiz, Daniel Podzamczer et al. · New England Journal of Medicine · 2003 · 293 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Frank A. Post, Graeme Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 218 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients

José M. Gallego‐Escuredo, Javier Gómez‐Ambrosi, Victoria Catalán et al. · International Journal of Obesity · 2014 · 209 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +13